This study evaluated the efficacy and safety of barnidipine for the treatment of mildto-moderate essential hypertension in Chinese patients. A total of 131 patients were randomized to receive either barnidipine (10 -15 mg) or felodipine (5 -10 mg) once daily for 4 weeks. Both drugs reduced blood pressure significantly, with ≥ 87% of patients obtaining a marked or moderate effect. The mean ± SD reductions in systolic and diastolic blood pressure were 19.2 ± 13.6 and 14.4 ± 7.0 mmHg, respectively, for barnidipine treatment, and 20.3 ± 11.3 and 14.7 ± 7.7 mmHg, respectively, for felodipine treatment. There were no significant differences between the two drugs in terms of anti-hypertensive effect, heart rate, laboratory test results or incidence of adverse events. More patients taking felodipine experienced palpitations, but this difference was not statistically significant. Barnidipine is as efficacious and safe as felodipine in the treatment of essential hypertension in Chinese patients.
Introduction
The control of hypertension is unsatisfactory in most populations. 1, 2 Compliance is one factor affecting blood pressure control; medications with fewer adverse effects that allow once-daily administration are more acceptable to patients. 3 Barnidipine is a long-acting calcium-channel blocker that can be given once daily. 4 -6 The efficacy of barnidipine for the treatment of hypertension has been demonstrated in both oriental people 7 -9 and Caucasians. 10 -15 This parallel-group clinical study compared the efficacy and safety profile of barnidipine with that of felodipine in the treatment of hypertension in Chinese patients. Felodipine was chosen as the comparator drug because of its common usage in China, its established effectiveness in the treatment of hypertension, and the similarity in the halflife of these two drugs.
Patients and methods PATIENTS
Chinese people living in China with mild-tomoderate hypertension were recruited to the study. Inclusion criteria included Chinese nationality, age 20 -75 years, and essential W Zhu, T Li, C Ni et al.
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hypertension with a diastolic blood pressure ≥ 95 mmHg but ≤ 110 mmHg. Patients with a diastolic blood pressure > 110 mmHg, secondary hypertension, severe heart failure, significant arrhythmia, severe dysfunction involving the respiratory system, liver, kidney, gastrointestinal system, neurological system, endocrine system or cardiovascular system, or significant metabolic abnormalities were excluded from the study.
All study participants provided written informed consent, and ethical approval was obtained from the Institutional Review Board of the hospitals.
TREATMENT SCHEDULE
Patients were randomly assigned to receive a starting dose of either 10 mg of barnidipine (Hypoca ® , Yamanouchi, Tokyo, Japan) or 5 mg of felodipine (Plendil ® , AstraZeneca, Luton, UK) once daily for 4 weeks. Other anti-hypertensive drugs and any other drugs that might affect blood pressure were prohibited during the study period.
Patients were followed up in the outpatient clinic after 2 and 4 weeks to check blood pressure changes, compliance and adverse events. Blood pressure changes after treatment were classified as adequate control if the decrease in the systolic blood pressure was ≥ 20 mmHg and/or the decrease in the diastolic blood pressure was ≥ 10 mmHg. A smaller or no reduction in blood pressure was defined as inadequate control of hypertension. The drug dose was titrated up by an increment of 5 mg at the 2-week follow-up visit if adequate control had not been achieved.
CLINICAL AND BIOCHEMICAL ASSESSMENT
Blood pressure readings were obtained after the patient had been sitting for 5 min and standing for 3 min in a darkened and quiet room, following the recommendations of the American Heart Association, 16 using a standard sphygmomanometer with an appropriate sized cuff. 17 Electrocardiography, chest radiography, blood chemistry determinations (fasting glucose, aspartate aminotransferase, alanine aminotransferase, urea nitrogen, creatinine, uric acid, cholesterol, triglyceride, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, sodium, potassium, chloride and calcium), a complete blood count and urinalysis were performed before and after the study period.
STATISTICAL ANALYSIS
Changes in blood pressure in the two treatment groups were compared using the Student's paired t-test. Adequacy of blood pressure control in the two groups was compared using the χ 2 test. The incidence of adverse events was analysed using Fisher's exact test. P-values < 0.05 were considered statistically significant.
Results
A total of 131 hypertensive patients were included in the study, 68 in the barnidipine group and 63 in the felodipine group. The demographic and clinical characteristics of the patients in the two treatment groups are given in Table 1 . Two patients in the felodipine group were lost to follow-up after receiving the first 2-week course of medication. Data from all 131 patients were analysed for tolerability; data from the 129 patients completing the study protocol were analysed for efficacy. The numbers of patients requiring an increase in the dose of barnidipine (from 10 to 15 mg) or felodipine (from 5 to 10 mg) were 39 patients (57.4%) and 29 patients (48.3%), respectively.
Both barnidipine and felodipine reduced the systolic and diastolic blood pressure W Zhu, T Li, C Ni et al. Barnidipine and felodipine in Chinese patients with essential hypertension significantly (P < 0.01) at 4 weeks compared with baseline (Table 2 ). There were no significant differences in baseline blood pressure, blood pressure after treatment or changes in blood pressure with treatment between the two groups of patients. In addition, there were no significant differences between the two groups in heart rate before and after treatment, and the heart rate did not change significantly after treatment in either group. A total of 62 patients (91%) in the barnidipine group and 53 patients (87%) in the felodipine group experienced adequate control of their blood pressure after 4 weeks' treatment ( Table 3) .
No severe adverse effects were observed; only mild reactions were reported (Table 4 ). There was no significant difference in the number of episodes of adverse reactions between the two treatment groups. More patients taking felodipine experienced palpitations, but this difference was not statistically significant. Laboratory test results showed no significant changes after drug treatment in either group (data not shown). 
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Discussion
In the present study, once-daily administration of barnidipine, a calcium-channel blocker with a long half-life of 9.4 h, 4 was highly effective and well tolerated in Chinese patients with mild-to-moderate hypertension. These results are consistent with European, 11 -15 Japanese, 4 -8,18,19 Korean 9 and Taiwanese 20 studies, suggesting that there are no significant racial or cultural differences in the actions of barnidipine. Teramura et al. 21, 22 reported that this drug is metabolized by the cytochrome P450 isozyme 3A4 rather than the 2D6 or 2C19 isozymes, which are related to genetic polymorphism. In addition, the pharmacokinetic profile of barnidipine was similar in Japanese 4 and European 22 phase I studies.
The efficacy of barnidipine was similar to that of felodipine for the reduction of both systolic and diastolic blood pressures in the 410 present study, suggesting that a 10 -15 mg dose of barnidipine may have equivalent efficacy to 5 -10 mg of felodipine when used to treat Chinese patients with mild-tomoderate hypertension. This is consistent with the results seen in the Taiwanese study. 20 The safety analysis showed that neither barnidipine nor felodipine induced severe adverse events in the study participants. Side-effects were mild and transient. More patients experienced palpitations in the felodipine group than in the barnidipine group, but the difference was not statistically significant. In the Taiwanese study, 20 the incidence of palpitations was higher in those treated with felodipine than in those treated with barnidipine, but again the difference was not significant. It has been suggested that barnidipine does not induce reflex neurohormonal activation, which may offer a partial explanation for the observation that fewer patients taking barnidipine experienced palpitations.
Barnidipine has been shown to reduce blood pressure both in patients with essential hypertension in Japan, 5 -8 Korea, 9 Europe 10 -15 and Taiwan 20 and those with renal hypertension in Japan, 23 -25 Korea 26 and China. 27 Unlike angiotensin-converting enzyme inhibitors, it is especially useful for the treatment of severe renal hypertension. Barnidipine may be regarded as a safe and effective calcium antagonist with antihypertensive actions.
In conclusion, barnidipine, a dihydropyridine calcium-channel blocker with a long half-life, showed effective anti-hypertensive action and good tolerability similar to that of felodipine in Chinese patients with mild-tomoderate hypertension. The results of this study are consistent with those of previous studies in other populations, 7 -15 suggesting that there are no differences in the action of barnidipine among various races. Barnidipine is therefore an appropriate treatment worldwide for essential hypertension.
